Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Schwabl

Showing results (221-230 of 318) with videos related to

Pageof 32
Sort By:
Plos One|November 5, 2014
Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascitesMattias Mandorfer, Simona Bota, Philipp Schwabl, et al.
Digestive Diseases and Sciences|June 19, 2019
Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal HypertensionGeorg Semmler, Judith Stift, Bernhard Scheiner, et al.
Gastroenterology|March 18, 2014
Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitisMattias Mandorfer, Simona Bota, Philipp Schwabl, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2018
Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertensionM Mandorfer, B Scheiner, A F Stättermayer, et al.
AIDS (London, England)|January 14, 2016
Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver diseaseMattias Mandorfer, Philipp Schwabl, Sebastian Steiner, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2015
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responsesM Mandorfer, K Kozbial, C Freissmuth, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2018
Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severityM Mandorfer, P Schwabl, R Paternostro, et al.
Advances in Medical Sciences|March 10, 2022
Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertensionPhilipp Schwabl, Berit Anna Seeland, Florian Riedl, et al.
Scientific Reports|February 20, 2020
Bioimpedance spectroscopy for fluid status assessment in patients with decompensated liver cirrhosis: Implications for peritoneal dialysisElisabeth Schwaiger, Amrei Simon, Peter Wabel, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 15, 2020
Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsyJudith Stift, Georg Semmler, Katharina Wöran, et al.
Pageof 32

Showing results (221-230 of 318) with videos related to

Sort By:
Pageof 32
Plos One|November 5, 2014
Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascitesMattias Mandorfer, Simona Bota, Philipp Schwabl, et al.
Digestive Diseases and Sciences|June 19, 2019
Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal HypertensionGeorg Semmler, Judith Stift, Bernhard Scheiner, et al.
Gastroenterology|March 18, 2014
Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitisMattias Mandorfer, Simona Bota, Philipp Schwabl, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2018
Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertensionM Mandorfer, B Scheiner, A F Stättermayer, et al.
AIDS (London, England)|January 14, 2016
Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver diseaseMattias Mandorfer, Philipp Schwabl, Sebastian Steiner, et al.
Alimentary Pharmacology & Therapeutics|July 17, 2015
Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responsesM Mandorfer, K Kozbial, C Freissmuth, et al.
Alimentary Pharmacology & Therapeutics|January 30, 2018
Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severityM Mandorfer, P Schwabl, R Paternostro, et al.
Advances in Medical Sciences|March 10, 2022
Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertensionPhilipp Schwabl, Berit Anna Seeland, Florian Riedl, et al.
Scientific Reports|February 20, 2020
Bioimpedance spectroscopy for fluid status assessment in patients with decompensated liver cirrhosis: Implications for peritoneal dialysisElisabeth Schwaiger, Amrei Simon, Peter Wabel, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 15, 2020
Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsyJudith Stift, Georg Semmler, Katharina Wöran, et al.
Pageof 32